Isomorphic was spun out of Google’s AI research arm Google DeepMind in 2021, but remains a wholly owned subsidiary of its ...
The CEO of Google Mind has suggested clinical trials of the first drugs designed with the help of AI could begin this year.
Google's DeepMind spinoff Isomorphic Labs expects clinical trials of drugs designed using AI to start late this year.
Drugs developed by Alphabet’s drug discovery subsidiary and designed by artificial intelligence are expected to head to trial by the end of the year, according to a Google (GOOGL) executive.
An Alphabet-backed startup is poised to begin clinical trials of its first artificial intelligence-designed drug by year-end.
The pharma giant is partnering with software firms to imagine new drugs, find targets, and design clinical trials ...
Among the most important aspects of this story is AlphaFold, the artificial intelligence and foundation model platform developed by Google DeepMind and Isomorphic Labs, both Alphabet companies.
Pharmaceutical firms that specialize in utilizing AI to speed up the drug discovery process are soaring today.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback